abstract |
Disclosed is an isoform-specific antagonist of PAK kinase, which is preferably a molecule capable of modulating an interaction between Nck and a PAK isoform. In particular, αPAK, βPAK and γPAK specific inhibitors are disclosed. Also included are methods of treating diseases, preferably characterised by a defect in nerve regeneration, comprising modulating an activity of a PAK kinase isoform, preferably αPAK kinase or γPAK kinase, or both. |